San Diego, CA -- (SBWIRE) -- 10/18/2017 -- The Shareholders Foundation announces that an investor in NASDAQ:ICPT shares a lawsuit York over alleged violations of Federal Securities Laws by Intercept Pharmaceuticals Inc.

Investors who purchased shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The Company's lead product candidate, Ocaliva (obeticholic acid, or OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR. On May 31, 2016, Intercept announced that the U.S. Food and Drug Administration ("FDA") had approved Ocaliva for the treatment of patients with primary biliary cholangitis ("PBC").

On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company's treatment for primary biliary cholangitis ("PBC"), advising them that the drug has been tied to liver injuries and death among patients suffering from PBC.

The plaintiff claims that between May 31, 2016, and September 20, 2017, the Defendants made false and/or misleading statements and/or failed to disclose that Ocaliva entailed undisclosed safety risks, including death, to patients suffering from PBC, and that as a result of the foregoing, Intercept's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com